Regulus Therapeutics (NASDAQ:RGLS) Coverage Initiated by Analysts at StockNews.com
StockNews.com assumed coverage on shares of Regulus Therapeutics (NASDAQ:RGLS – Free Report) in a report issued on Sunday morning. The firm issued a sell rating on the biopharmaceutical company’s stock. A number of other equities analysts also recently commented on RGLS. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares […]
StockNews.com assumed coverage on shares of Regulus Therapeutics (NASDAQ:RGLS – Free Report) in a report issued on Sunday morning. The firm issued a sell rating on the biopharmaceutical company’s stock. A number of other equities analysts also recently commented on RGLS. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares […]
